Risk factor
Good trading liquidity
Profitability factor
Greatly overvalued vs peers
About
Suzhou Zelgen Biopharmaceuticals Co., Ltd. is a Chinese company engaged in the entire lifecycle of pharmaceutical products, from research and development to manufacturing and sales, within the People's Republic of China. Their product portfolio encompasses both small molecule and recombinant protein-based drugs, which are developed to treat a variety of serious health conditions. These include several types of cancer such as liver cancer, non-small cell lung cancer, colorectal cancer, thyroid cancer, and nasopharyngeal carcinomas. Furthermore, the company's medications address myelofibrosis, hemorrhage, and various hepatobiliary diseases. The firm was established in 2009 and is headquartered in Kunshan, located within the People's Republic of China.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI